Keith C. Kummerfeld - Apr 17, 2023 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Role
Senior Vice President of Finance (Principal Accounting Officer)
Signature
/s/ Ilan Katz, attorney-in-fact
Stock symbol
ARCT
Transactions as of
Apr 17, 2023
Transactions value $
-$133,950
Form type
4
Date filed
4/19/2023, 04:57 PM
Previous filing
Dec 16, 2022
Next filing
Jul 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARCT Common Stock Options Exercise $14.6K +1.03K +108.53% $14.12 1.98K Apr 18, 2023 Direct
transaction ARCT Common Stock Options Exercise $40.7K +4.5K +227.16% $9.04 6.48K Apr 18, 2023 Direct
transaction ARCT Common Stock Options Exercise $7.17K +1.44K +22.17% $4.99 7.92K Apr 18, 2023 Direct
transaction ARCT Common Stock Sale -$196K -6.97K -88% $28.18 950 Apr 18, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARCT Employee Stock Option (right to buy) Options Exercise $0 -1.03K -10.31% $0.00 8.97K Apr 17, 2023 Common Stock 1.03K $14.12 Direct F3
transaction ARCT Employee Stock Option (right to buy) Options Exercise $0 -4.5K -15% $0.00 25.5K Apr 17, 2023 Common Stock 4.5K $9.04 Direct F3
transaction ARCT Employee Stock Option (right to buy) Options Exercise $0 -1.44K -14.37% $0.00 8.56K Apr 17, 2023 Common Stock 1.44K $4.99 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $28.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on April 17, 2023.
F3 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

Remarks:

Senior Vice President of Finance (Principal Accounting Officer)